Donnerstag, 10.07.2014 17:45 von PR Newswire | Aufrufe: 111

SALIX PHARMACEUTICALS, LTD. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Merger

Medikamente können bei neurologischen Erkrankungen helfen (Symbolbild). © cosmin4000 / iStock / Getty Images Plus / Getty Images https://www.gettyimages.de/

PR Newswire


WILMINGTON, Del., July 10, 2014 /PRNewswire/ -- Rigrodsky & Long, P.A.:

  • Do you own shares of Salix Pharmaceuticals, Ltd. (NASDAQ GS: SLXP)?
  • Did you purchase any of your shares prior to July 8, 2014?
  • Do you think the proposed merger value is too low?
  • Do you want to discuss your rights?

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Salix Pharmaceuticals, Ltd. ("Salix" or the "Company") (NASDAQ GS: SLXP) regarding possible breaches of fiduciary duties and other violations of law related to the Company's entry into an agreement to merge with Cosmo Technologies Limited ("Cosmo Tech"), a subsidiary of Cosmo Pharmaceuticals S.p.A. ("Cosmo").

Click here to learn more: http://www.rigrodskylong.com/investigations/salix-pharmaceuticals-ltd-slxp.

Under the terms of the agreement, Salix will become a wholly-owned subsidiary of Irish domiciled Cosmo Tech, which will change its name to Salix Pharmaceuticals, plc and is expected to have its ordinary shares listed and traded on the NASDAQ Global Select Market.  Shareholders of Salix will receive one ordinary share of Salix Pharmaceuticals, plc in exchange for each share of Salix Pharmaceuticals, Ltd common stock they own at closing.   

The investigation concerns whether Salix's board of directors failed to adequately shop the Company and obtain the best possible value for Salix's shareholders before entering into an agreement with Cosmo.

If you own the common stock of Salix and purchased your shares before July 8, 2014, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803, by telephone at (888) 969-4242; by e-mail to info@rl-legal.com, or at: http://www.rigrodskylong.com/investigations/salix-pharmaceuticals-ltd-slxp.

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, on behalf of shareholders in states and federal courts throughout the United States.

Kurse

  

Attorney advertising.  Prior results do not guarantee a similar outcome.

CONTACT:                                                                                              

Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242
(302) 295-5310
Fax: (302) 654-7530
info@rl-legal.com
http://www.rigrodskylong.com

SOURCE Rigrodsky & Long, P.A.

Werbung
Mehr Nachrichten zur CureVac Aktie kostenlos abonnieren
E-Mail-Adresse
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptieren Sie die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.

Andere Nutzer interessierte auch dieser Artikel: